header photo: About Us

Strategic Partnerships


In May 2013 we acquired worldwide rights to SCY-078, a compound resulting from our research collaboration with Merck. SCY-078 is an antifungal compound from a novel class with potential to treat invasive fungal infections caused by Candida and Aspergillus.


In August 2013, we announced an agreement with R-Pharm CJSC, granting them exclusive rights to develop and commercialize SCY-078 in Russia, Turkey, and certain Balkan, Central Asian, Middle Eastern and Northern African countries. Invasive fungal infections are a serious health concern in these countries and we are pleased to be working with R-Pharm to develop SCY-078 for these patients.